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Abstract
Background: Neuroblastoma (NB) is the most common extracranial solid tumour of childhood.
Several genomic imbalances correlate to prognosis in NB, with structural rearrangements, including
gene amplification, in a near-diploid setting typically signifying high-risk tumours and numerical
changes in a near-triploid setting signifying low-risk tumours. Little is known about the temporal
sequence in which these imbalances occur during the carcinogenic process.
Methods: We have reconstructed the appearance of cytogenetic imbalances in 270 NBs by first
grouping tumours and imbalances through principal component analysis and then using the number
of imbalances in each tumour as an indicator of evolutionary progression.
Results: Tumours clustered in four sub-groups, dominated respectively by (1) gene amplification
in double minute chromosomes and few other aberrations, (2) gene amplification and loss of 1p
sequences, (3) loss of 1p and other structural aberrations including gain of 17q, and (4) whole-
chromosome gains and losses. Temporal analysis showed that the structural changes in groups 1–
3 were acquired in a step-wise fashion, with loss of 1p sequences and the emergence of double
minute chromosomes as the earliest cytogenetic events. In contrast, the gains and losses of whole
chromosomes in group 4 occurred through multiple simultaneous events leading to a near-triploid
chromosome number.
Conclusion: The finding of different temporal patterns for the acquisition of genomic imbalances
in high-risk and low-risk NBs lends strong support to the hypothesis that these tumours are
biologically diverse entities, evolving through distinct genetic mechanisms.
Background
Neuroblastoma (NB) originates from the postganglionic
cells of the sympathetic nervous system and is the most
common extracranial solid tumour of childhood. Four of
five children with NB are diagnosed before 4 years of age
and it is the most common tumour in infancy, becoming
less frequent in each succeeding year. In spite of vast
knowledge about the biology of NB, the long-term sur-
vival is still less than 30% for children with high-risk
tumours [1]. It is a well-known fact that acquired chromo-
some changes in neoplastic cells contribute to tumour
development. This is well illustrated by NB, where several
genomic imbalances have been shown to correlate to
prognosis. Amplification of the MYCN oncogene in dou-
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ble minute chromosomes (dmin) or homogeneously
staining regions (hsr), loss of heterozygosity for the short
arms of chromosomes 1 (1p) and 3 (3p) and the long arm
of chromosome 11 (11q), and gain of sequences from
17q have all been shown to predict a poor prognosis [2-
5]. On the other hand, tumours with hyperdiploid or
near-triploid karyotypes dominated by whole-chromo-
some gains and losses have a considerably better progno-
sis and may even undergo spontaneous regression [3,6,7].
The former pattern of imbalances is generally more com-
mon in patients above 12–18 months of age, whereas the
latter one is more common in younger children.
Despite the importance of genomic imbalances for the
clinical outcome of NB, little is yet known about the proc-
esses through which such imbalances are acquired. We
have previously established a method for statistically
assessing the relative time of occurrence (TO) of cytoge-
netic aberrations in tumours by determining the degree of
cytogenetic complexity at which each aberration typically
occurs [8-12]. The possibility to screen for genomic imbal-
ances in NB at a high resolution level has improved dra-
matically over the last few years, with the introduction of
array-based whole-genome screening techniques [3,13-
15]. However, with some notable exceptions [15], studies
of NB by such high-resolution screening methods have so
far only included a relatively small number of cases. In
contrast, several hundred NBs have been analysed by
chromosome banding methodology and curated karyo-
types of published cases are available in a public database
[16]. In order to maximise the number of cases used for
temporal reconstruction, we therefore chose to analyse
data from this latter source, first by grouping imbalances
frequently occurring together, and then by establishing
their relative order within each group. We finally corre-
lated these abnormalities to basic clinical parameters. Our
data indicate that near-diploid, highly aggressive,
tumours and near-triploid, less aggressive, tumours
acquire their respective chromosome aberrations through
different temporal processes: While the near-diploid
tumours accumulate clonal abnormalities through
sequential genomic rearrangements, the second group of
tumours obtains their near-triploid status by multiple
simultaneous events.
Methods
General strategy
Karyotypes from 270 NB patients available in the Mitel-
man Database of Chromosome Aberrations in Cancer
were downloaded as text files. ISCN karyotypes [17] were
converted into binary data sets denoting the status of each
chromosome band as 1 if gained, -1 if lost, and 0 if neither
gained nor lost. [18]. Whole genome profiles of all chro-
mosomes were then created and chromosome segments
gained or lost in >5% of the tumours were selected for fur-
ther analysis (Table 1). In the event that one or more seg-
ments of a chromosome deviated >5% units from the
whole-chromosome profile, these segments were scored
separately from the whole-chromosome imbalances. Each
karyotype was then assessed for the presence or absence of
the selected imbalances. The number of imbalances per
tumour (NIPT) was calculated and cases with at least one
of the chosen imbalances were selected for further analy-
sis, resulting in 259 cases. Also, if available, the age of the
patient as well as tumour stage according to the Interna-
tional Neuroblastoma Staging System [19] was retrieved
from the original publication of each case. Age and stage
were combined into a simplified clinical risk stratification
as follows: patients with stage 1-, 2- and 4s-disease were
assigned low risk irrespective of age, whereas patients with
stage 3-disease irrespective of age and stage 4-disease <1
years of age were assigned intermediate risk. Stage 4 cases
>1 years of age were classified as high risk.
Statistical analyses
To search for possible patterns of correlations between the
imbalances, principal component analysis (PCA) was per-
formed using the Statistica software package (Statsoft,
Tulsa, OK). PCA is a standard multivariate method fre-
quently used to search for underlying structures in data
sets [18]. In short, principal components are linear com-
binations of the original variables, orthogonal, and
ordered with respect to their variance so that the first prin-
cipal component has the largest variance. To analyse
imbalances, these were used as variables and the individ-
ual tumours as the observations; this will group imbal-
ances frequently seen in the same tumours. Tumour cases
were analysed by using the tumours as variables and the
imbalances as cases. This will group tumours with similar
karyotypic profiles. The TO was determined essentially as
described [8]. Briefly, all tumours with a given imbalance
were selected and the distributions of NIPT plotted. The
modes of the NIPT distributions were then used as values
for TO. To obtain a better estimate of the TO, the selected
distributions were re-sampled with replacement (boot-
strapped) 1,000 times and the TO scored after each re-
sampling [20]. The mean of the bootstrapped TO values
was then used as the TO for the given imbalance and the
bootstrapped 25th and 75th percentiles calculated. For
the bootstrap estimates, re-sampling software from Resa-
mpling Stats (Arlington, VA) was used.
Results
Basic statistics
Of the 270 cases, 59% were near-diploid, 23% were near-
triploid, and 15% were near-tetraploid. The remaining 3%
either had ploidies defined as intervals spanning different
ploidy levels or had multiple clones at different levels. In
total, 14 whole-chromosome gains, 21 whole-chromo-
some losses, two segmental chromosome gains, and fourJournal of Carcinogenesis 2007, 6:15 http://www.carcinogenesis.com/content/6/1/15
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segmental chromosome losses were found in >5% of the
tumours (Table 1). Double minute chromosomes (dmin)
and homogeneously staining regions (hsr) were also
present in >5% of the karyotypes. One or more of these
abnormalities were present in 259 (93%) of the total
number of tumours.
Principal component analysis of imbalances
To assess whether some of the selected abnormalities pref-
erentially occurred together with one or more other
abnormalities, we performed PCA of the karyotypic data.
This revealed three distinct clusters of aberrations, one
containing all the whole-chromosome gains, a second
containing all whole-chromosome losses, and a third con-
taining all imbalances resulting from structural rearrange-
ments,  i.e.  segmental gains, segmental losses, hsr and
dmin (Figure 1). Although the distance between two aber-
rations in the PCA diagram is ultimately a representation
of the correlation between the frequencies of these two
abnormalities in any sub-set of tumours, the relationships
between the abnormalities were often complex. For exam-
ple, 1p- and dmin were located outside the main cluster of
structural rearrangements and the presence of one of these
changes correlated only weakly with the other (r = +0.13;
P < 0.01). Of the total 57 cases with dmin, 35 showed 1p-
(61%). Conversely, of the 133 cases with 1p-, only 35
(26%) also showed dmin. Hence, the clustering of imbal-
ances into whole-chromosome gains, losses, and struc-
tural changes by PCA was not always translatable into
straightforward concurrence of abnormalities within cases
belonging to the same cluster. Nevertheless, the PCA of
genomic imbalances suggested that most NBs could be
classified into groups based on the presence in the karyo-
type of whole-chromosome gains, whole-chromosome
losses, or structural changes.
Principal component analysis of cases
In order to further explore the subdivision of NB accord-
ing to cytogenetic imbalances, we performed PCA in the
reverse fashion, i.e. using the genomic imbalances as
observations and the cases as variables. A scatter plot of all
259 cases according to the two first principal components
resulted in four clusters (Figure 2a and 2b; Table 2): (1)
those with dmin without 1p-, (2) those with 1p- as well as
dmin or hsr, (3) those with 1p- without dmin or hsr, and
(4) those with neither 1p-, nor dmin. Some structural
imbalances other than dmin, hsr, and 1p- also showed an
uneven distribution among the four groups, with +17q
being particularly prevalent in group 3 and 11q- being
more common in groups 3 and 4 than in groups 1 and 2.
Cases with hsr without 1p- or dmin located separately.
However, hsr was present only in 16 cases, of which 10
had either dmin, 1p-, or both. When adding the third
principal component, groups 3 and 4 could be further
sub-classified into karyotypes dominated by whole chro-
Table 1: Relative frequency and age/stage/risk correlates of 
cytogenetic abnormalities
Karyotype 
features
Frequencies 
(%)
Overepresented 
group (P value)
Ploidy level Age Stage Risk
2n 59 - - -
3n 23 <1 ys (6 × 10-4) 1–2 (4 × 10-5) L (1 × 10-4)
4n 15 - - -
Whole 
chromosome 
gains
+17 15 <1 ys (3 × 10-4) 1–2 (4 × 10-5) L (7 × 10-6)
+7 13 - - -
+18 11 - - -
+12 10 <1 ys (3 × 10-3) 1–2 (2 × 10-4) L (2 × 10-4)
+20 9 - - -
+13 9 - - -
+9 8 <1 ys (2 × 10-4) 1–2 (2 × 10-8) L (3 × 10-7)
+6 7 - - -
+8 7 - - -
+21 6 - - -
+5 6 - - -
+11 5 - - -
+2 5 - - -
+1 5 - - -
Whole 
chromosome 
losses
-X 21 - - -
-11 14 - - -
-10 14 - - -
-15 14 - - -
-19 14 - - -
-4 14 - 1–2 (5 × 10-4) L (5 × 10-4)
-3 12 - - -
-9 11 - - -
-14 11 - - -
-17 11 - - -
-22 11 - - -
-21 11 - - -
-13 10 - - -
-16 10 - - -
-8 9 - - -
-6 9 - - -
-20 9 - - -
-5 8 - - -
-2 6 - - -
-18 6 - - -
-12 5 - - -
Partial 
chromosome 
gains
+1q 
(1p31q44)
15 - - -
+17q 
(17q12q25)
13 - - -
Partial 
chromosome 
losses
1p- (1p36p11) 48 - - H (4 × 10-3)
11q- 
(11q23q25)
8- - -
3p- (3p26p12) 8 - - -
6q- (6q23q27) 6 - - -
Gene 
amplifications
dmin 20 1–3 (8 × 10-5) - H (6 × 10-3)
hsr 6 - - -
Over-representation tested by Chi-Square test with significance level set at P < 
0.01. Abbreviations: ys, years; L, low risk; H, high risk; -, not significantly over-
represented in any subgroup.Journal of Carcinogenesis 2007, 6:15 http://www.carcinogenesis.com/content/6/1/15
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mosomes gains and karyotypes dominated by whole-
chromosome losses (Figure 2c and 2d). In group 4, whole
chromosome gains were generally much more prevalent
than in the other three groups, whereas group 3 was gen-
erally dominated by losses. Groups 1 and 2 showed only
little variability along the third principal component,
most probably because whole chromosome imbalances
were rare in both these subgroups.
Correlation to age, stage, and risk classification
Age and tumour stage could be identified in 252 and 217
cases, respectively. In many of the original publications,
age was given in full years only and more refined age sub-
division could therefore not be made. Age and stage were
combined into a simplified clinical risk classification as
described in Materials and Methods. This resulted in the
identification of 48 low-risk, 24 intermediate-risk, and
146 high-risk patients. To establish whether any of the
selected imbalances were present more or less often than
expected from a random distribution we first calculated
the expected number of tumours with a certain imbalance
for each sub-group and compared these distributions to
the true distributions in our material. Suspected over/
under-representations were tested with Chi-square test.
With respect to the age of tumour presentation, tumours
with a near-triploid karyotype as well as tumours with
gains of whole chromosomes 9, 12 and 17 (i.e. abnormal-
Table 2: Cytogenetic subgroups derived from PCA1
Chromosomal 
imbalances
1p- negative 
dmin positive
1p- positive 
dmin/hsr 
positive
1p- positive 
dmin/hsr 
negative
1p- negative 
dmin/hsr 
negative
Number of 
cases
21 40 93 97
Whole 
chromosome 
gains
+ 1 0839
+ 2 03310
+ 3 50210
+ 5 03312
+ 6 00613
+7 5 3 11 25
+ 8 03512
+ 9 05416
+11 10 0310
+ 1 2 03820
+ 1 3 53518
+17 5 0 10 32
+18 5 3 12 18
+20 0 5 10 15
+ 2 1 53214
Whole 
chromosome 
losses
- 2 08410
-3 0 5 16 16
-4 0 5 13 24
- 5 08512
- 6 55913
-8 10 8 10 12
-9 0 8 13 15
-10 5 13 15 19
-11 0 8 14 24
- 1 2 0069
-13 0 3 16 11
-14 10 8 13 12
-15 0 10 19 16
-16 5 8 6 19
-17 5 13 12 12
- 1 8 0549
-19 10 5 13 22
-20 5 5 9 12
-21 5 8 13 14
-22 5 5 13 15
-X 14 5 27 29
Partial 
chromosome 
gains
+1q 
(1p31q44)
19 13 13 21
+17q 
(17q12q25)
5820 12
Partial 
chromosome 
losses
1p- (1p36p11) 0 100 100 0
3p- (3p26p12) 10 5612
6 q -  ( 6 q 2 3 q 2 7 ) 5596
11q- 
(11q23q25)
5310 11
Gene 
amplifications
hsr 0 23 0 0
dmin 100 90 0 0
1Imbalances present at a frequency of 10% or more are in bold type; imbalances 
included in sub-group definitions are underlined.
Principal component analysis of recurrent imbalances in neu- roblastoma Figure 1
Principal component analysis of recurrent imbalances in neu-
roblastoma. A three-dimensional representation based on 
the three first principal components is shown. Three major 
clusters of imbalances are seen; one composed of all struc-
tural aberrations, one containing all whole chromosome 
gains, and one with all whole chromosome losses. PC1, PC2, 
PC3 are principal components 1, 2, and 3, respectively.Journal of Carcinogenesis 2007, 6:15 http://www.carcinogenesis.com/content/6/1/15
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ities characteristic of group 4) were all over-represented in
patients less than 1 year of age (Figure 3). The same abnor-
malities were over-represented in tumours of lower stages
(1–2) and in low-risk tumours (Figure 2e and 2f). In addi-
tion, loss of whole chromosome 4 was over-represented
in low-stage (1–2) and low-risk tumours. In contrast, 1p-
and dmin (characteristic of groups 1–3) were over-repre-
sented in high-risk tumours; dmin were also over-repre-
sented in patients >1 year and <4 years of age.
Temporal development of chromosome changes
The total number of imbalances in a tumour can be used
as an approximation of its state of clonal evolution [8-
12,18]. Hence, the modal number of imbalances at which
a specific cytogenetic abnormality occurs can be used to
approximate its time of occurrence (TO) in relation to
other abnormalities in the same sample of tumours. The
present TO analysis showed that the structural rearrange-
ments appeared in a relatively specific order, initiated by
1p- and dmin (TO = 1–2), followed by +17q, +1q, 3p-, 6q-
, hsr (TO = 2–4), and finally by 11q- (TO = 3–6) (Figure
4). For the whole-chromosome changes, the TO values
were confined between 8 and 14, with highly overlapping
25th–75th percentile intervals. Accordingly, there was no
difference in TO between gains and losses of whole chro-
mosomes. Hence, each whole-chromosome abnormality
was most probably acquired together with one or several
other abnormalities of the same type.
Discussion
Studies of the tumour genome by chromosome banding
analysis suffer from several shortcomings, e.g. difficulties
in obtaining a sufficient number of mitotic cells for anal-
ysis, overgrowth of normal cells in tissue culture, poor
quality of chromosome preparation, and an inherently
low resolution. Nevertheless, several large cytogenetic
series of NB, some of which have been complemented by
multicolour fluorescence in situ hybridisation analysis,
Clustering of tumour cases based on chromosomal imbalances using principal component analysis Figure 2
Clustering of tumour cases based on chromosomal imbalances using principal component analysis. In a, c, and e, two-dimen-
sional representations based on the 1st and 2nd principal components are shown and in b, d, and f, three-dimensional repre-
sentations are shown. In essence, the three-dimensional representations show a side-view and the two-dimensional 
representations a top-view of the clustering results. Colour codes in a and b: red, cases with 1p- without hsr/dmin; green, cases 
with 1p- and hsr/dmin; black, cases with dmin without 1p- ; purple, cases with hsr without 1p-; blue, other cases. Colour codes 
in c and d: red, tumours containing a higher number of whole-chromosome losses than whole-chromosome gains; green, 
tumours containing a higher number of gains than losses; empty circles, tumours not containing any whole-chromosome 
abnormalities. Colour codes in e and f: red, high risk tumours; green, low risk tumours; blue, intermediate risk tumours; empty 
circles, tumours with insufficient data for classification.Journal of Carcinogenesis 2007, 6:15 http://www.carcinogenesis.com/content/6/1/15
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have been reported with a high frequency of cases show-
ing cytogenetic abnormalities and with detailed karyotype
descriptions [6,21-25]. In the present study, we have sum-
marised the published cytogenetic data in NB and per-
formed a comprehensive and unbiased statistical
analyses. PCA of chromosomal imbalances revealed three
distinct clusters of imbalances that tended to occur
together in the same tumours, i.e. whole-chromosome
gains, whole-chromosome losses, and structural changes.
Of the structural changes, 1p- and dmin were by far the
most common, occurring in 48% and 20% of the
tumours, respectively. Indeed, when PCA of the tumour
cases was performed, these two changes largely domi-
nated the first two principal components. The third prin-
cipal component was dominated by the spectrum of
whole chromosome changes. In summary, the PCAs indi-
cated that the accumulated cytogenetic data could warrant
sub-classification of NBs into at least four groups, i.e.
those characterised by (1) dmin and few other imbal-
ances, (2) dmin, 1p-, and few other imbalances, (3) 1p-,
other structural changes such as +17q, and whole chromo-
some losses, and finally (4) whole-chromosome gains
and losses. Groups 1–3 were dominated by the structural
abnormalities associated with high-risk tumours in the
present study (dmin/hsr, 1p), while group 4 was domi-
nated by numerical abnormalities associated with low-
risk tumours (+9, +12, +17, and -4).
Several authors have suggested that NB can be sub-divided
into at least two biological entities, reflecting the hetero-
geneous scenario observed in NB patients [26]. The first
group is characterised by a near-diploid karyotype and
genetic imbalances based on structural cytogenetic
changes. Among these, the NB with MYCN amplification,
also often showing 1p-, generally present with high-stage
disease and are rapidly progressive, whereas the tumours
without  MYCN  amplification but with other structural
changes such as loss of heterozygosity for 11q typically
occur in patients with slowly progressive but often fatal
disease. These two subgroups most closely resemble
groups 1–2 and 3, respectively in the present study. The
other main biological group is characterised by a near-tri-
ploid karyotype with few structural chromosome changes,
occurring in infants with confined disease and a very good
prognosis. This group corresponds to our group 4. Hence,
despite its inherent methodological limitations, the
Temporal analysis Figure 4
Temporal analysis. The estimated TO values are indicated by 
open squares. The range of the 25th and 75th quartiles is 
indicated by filled boxes. The imbalances are ordered with 
respect to their estimated TO values.
Frequencies across age groups Figure 3
Frequencies across age groups. Lines represent triploid 
cases, cases with +9, +12, +17, -4, and dmin in patients aged 
0 (below 1), 1, 2, 3, and above 3 years of age.Journal of Carcinogenesis 2007, 6:15 http://www.carcinogenesis.com/content/6/1/15
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present study identified clinico-genetic sub-groups that
were largely similar to those identified by other recent
studies using comparative genome hybridisation and oli-
gonucleotide arrays [3,15].
It has been suggested that diploid and triploid NB may
arise from a common tetraploid precursor undergoing
tripolar cell division [26,27]. The first type of daughter cell
(2n) may give rise to the near-diploid, typically aggressive,
tumours characterised by structural chromosomal
changes, particularly 1p-, 11q-, +17q, and dmin (our
groups 1–3). The second type of daughter cell (3n) may
evolve into the near-triploid, typically indolent, tumours
harbouring whole-chromosome changes, such as +9, +12,
and +17 (our group 4). Although a highly attractive
hypothesis, little empirical data have so far been pre-
sented to substantiate that these two biological NB enti-
ties in fact evolve through different evolutionary
pathways. If the near-diploid tumours were actually
derived from a tripolar tetraploid mitosis, segregating into
haploid sets as originally suggested by Kaneko and Knud-
son [27], this could result in three possible sex chromo-
some complements in the resulting 2n cells, i.e. XY, XX,
and YY. Of these, XY would be twice as probable as each
of the two other two. It can be further argued that the YY
cells, having nullisomy for the X chromosome, are not
likely to survive. Hence, if the 2n tumours resulted from a
tripolar cell division of a tetraploid cell, this would imply
that 1/3 of the NB with 2n ploidy in male patients should
have an XX chromosome complement. None of the 90
karyotypes from male patients with 2n tumours in the
present series, showed such sex-reversal. However, this
chain of reasoning assumes that somatic cell feminisation
would not be lethal on the cellular level, which cannot be
excluded at present. Furthermore, it does not rule out that
tripolar division of a tetraploid cell lies behind the gener-
ation of near-triploid tumours, in which such somatic sex
reversal would not occur if one assumed segregation into
haploid sets.
In the present study we used the number of chromosome
imbalances at which a certain chromosomal aberration
typically occurred to model the evolution of genomic
changes in NB. This approached has previously been used
to delineate the temporal development of chromosome
aberrations in several other tumours [9-11,28,29]. Our
analysis showed that the structural changes occurred in a
step-wise fashion, with loss of 1p sequences and the emer-
gence of double minute chromosomes as the earliest
cytogenetic events, followed by gain of 1q and 17q, loss of
3p and 6q, acquisition of homogeneously staining
regions, and finally loss of 11q. In contrast, the gains and
losses of whole chromosomes occurred more or less
simultaneously, in a fashion similar to that suggested for
the acquisition of whole-chromosome gains in hyperdip-
loid childhood leukemias [30]. This supports the notion
that the numerical chromosome changes in 3n NB may
arise through a single rare event, such as an asymmetrical
mitotic cell division. In contrast, the 2n tumours appear to
develop through the sequential acquisition of structural
changes. Such a step-wise evolution of genome imbal-
ances has been found in many common carcinomas, such
as colorectal cancer, breast cancer, ovarian cancer, and
bladder cancer [8]. It is possible that this step-wise acqui-
sition of clonal changes reflects genome plasticity, which
might explain why 2n tumours are more resistant to treat-
ment than 3n tumours.
Conclusion
Our finding of different dynamics for the acquisition of
chromosome changes in the two main biological subsets
of NB, taken together with the PCA classification of
tumours into those with structural and those with numer-
ical changes, lends strong support to the hypothesis that
high-risk and low-risk NBs are biologically diverse enti-
ties, evolving through at least two distinct genetic mecha-
nisms.
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